<DOC>
	<DOCNO>NCT01235260</DOCNO>
	<brief_summary>The purpose study evaluate risk cancer incidence mortality associate use REGRANEX ( becaplermin ) patient diabetes member U.S. Veterans Health Administration .</brief_summary>
	<brief_title>Becaplermin Use Cancer Risk Patient Population U.S. Veterans With Diabetes</brief_title>
	<detailed_description>This observational study patient diabetes eligible care national Department Veterans Affairs Health Care System ( VA ) , represent large sample older adult integrate health care system U.S. comprehensive electronic medical record linkable health survey data . REGRANEX ( becaplermin ) topical medication use treat lower extremity diabetic neuropathic ulcer . VA patient diabetic foot ulcer prior history cancer receive treatment becaplermin compare group similar patient receive treatment becaplermin . Becaplermin user ( time initial dispense becaplermin ) becaplermin nonusers follow forward time 8 year identify new cancer cancer relate death , confirmation case registries medical chart review . This observational study ; investigational drug administer .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<criteria>Patients diabetic foot ulcer member U.S Department Veterans Affairs Health Care System ( VA ) History cancer ( include nonmelanoma skin cancer ) prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>REGRANEX ( becaplermin )</keyword>
	<keyword>Platelet-derived growth factor BB</keyword>
	<keyword>Cancer</keyword>
	<keyword>Cancer incidence</keyword>
	<keyword>Cancer mortality</keyword>
	<keyword>Lower Extremity Diabetic Neuropathic Ulcer</keyword>
</DOC>